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There have been significant advances in the treatment of
melanoma via the use of targeted therapy and immu-
notherapy, however a significant proportion of patients
still progress on treatment. Intense research efforts are
underway to better understand resistance, and multiple
molecular resistance mechanisms to targeted therapy
have been identified. There is a growing appreciation of
intra-tumoral genetic heterogeneity as a contributor to
resistance to therapy, however immune heterogeneity
within multiple solid tumors within the same patient has
been less well studied. The goal of the present study is to
better understand the leukocyte infiltrate in multiple
melanoma tumors within the same patient at the time of
disease progression, with the potential to identify action-
able strategies to overcome resistance to therapy. In these
studies, we prospectively evaluated 8 tumors from
4 patients progressing on either targeted therapy or immu-
notherapy. Tissues were evaluated by polychromatic flow
cytometry in combination with immunohistochemical
analysis of tissue sections. Specifically, we utilized 5 panels
of antibodies for flow cytometry to gain a deep analysis of
the leukocyte composition with a focus of 1) T cells/Tregs,
2) NK/T/B cells, 3) tumor associated macrophages and
fibroblasts, 4) dendritic cells, and 5) polymorphonuclear
leukocytes. Results demonstrate significant immune het-
erogeneity between different melanoma tumors within the
same patient in the majority of patients studied (3 of 4).
Of note, there were significant differences in CD4+, CD8+,
and regulatory T cells (p < 0.05) with similar activation
markers but differences in T cell memory markers. There
were no significant differences in tumor-associated
macrophages or dendritic cells. Together, these data sug-
gest that there may be significant immune heterogeneity
between different tumors within a single patient with
metastatic melanoma. This has important clinical implica-
tions, as a single tumor biopsy sample may not be repre-
sentative of the immune profile of multiple tumors within
the same individual. It is provocative to contemplate that
this could account for variable responses to therapy, how-
ever this is a hypothesis that needs to be tested carefully in
a much larger data set. Nonetheless, these findings have
potential significant implications for the treatment of
melanoma and other cancers.
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